• Mucosal subtype (p = 0.022), LDH level (p = 0.005), no extracranial metastasis (p = 0.01), concurrent liver metastasis (p = 0.004), local treatment (p = 0.001) and use of PD-1 inhibitors (p < 0.0001) were independent prognostic factors for OS• Mucosal subtype BrM had poor response to PD-1 inhibitors (p = 0.007), with a shorter intracranial PFS than other subtypes• In patients with BRAF mutated melanoma BrM, first-line BRAF/MEK inhibitor therapy had an advantage in OS compared to the first-line anti-PD-1 therapy group (p = 0.043). This evidence concerns the gene PDCD1 and melanoma.